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Abstract: Amyloid aggregation is linked to a large number of human disorders, from neurodegenerative 
diseases as Alzheimer’s disease (AD) or spongiform encephalopathies to non-neuropathic localized 
diseases as type II diabetes and cataracts. Because the formation of insoluble inclusion bodies (IBs) 
during recombinant protein production in bacteria has been recently shown to share mechanistic features 
with amyloid self-assembly, bacteria have emerged as a tool to study amyloid aggregation. Herein we 
present a fast, simple, inexpensive and quantitative method for the screening of potential anti-aggregating 
drugs. This method is based on monitoring the changes in the binding of thioflavin-S to intracellular IBs 
in intact Eschericchia coli cells in the presence of small chemical compounds. This in vivo technique 
fairly recapitulates previous in vitro data. Here we mainly use the Alzheimer’s related -amyloid peptide 
as a model system, but the technique can be easily implemented for screening inhibitors relevant for other 
conformational diseases simply by changing the recombinant amyloid protein target. Indeed, we show 
that this methodology can be also applied to the evaluation of inhibitors of the aggregation of tau protein, 
another amyloidogenic protein with a key role in AD. 
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1. INTRODUCTION 
Amyloid aggregation is a process by which some monomeric peptides or proteins undergo a 
conformational change into misfolded species that expose specific amyloid-prone sequences usually 
increasing hydrophobic surfaces, otherwise generally buried in folded structures. This increases 
intermolecular attractive forces favoring the formation of steric zipper (two self-complementary -sheets 
that form the spine of an amyloid fibril), rendering them prone to self-associate into increasingly ordered 
and insoluble oligomeric and polymeric species or fibrils [1-3]. Amyloidogenic proteins, despite having 
distinct amino acid composition, length, and in vivo distribution, eventually lead to similar highly ordered 
aggregated structures. Amyloid structures have a core region formed by repetitive arrays of β-sheets 
oriented parallel to the fibril axis [1,4,5], and display similar biochemical, biophysical, tinctorial and 
morphological properties [6]. Even though amyloid aggregates can play specific physiological roles [1,7], 
in most cases they seem to be the root cause of a number of human diseases, the so-called amyloidoses, 
conformational diseases or protein misfolding disorders [1,6]. These include a broad range of disorders, 
from neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases or 
transmissible sporadic encephalopathies to non-neurodegenerative systemic and localized amyloidoses 
such as lysozyme and fibrinogen amyloidosis or type II diabetes and cataracts [8]. 
Alzheimer’s disease (AD) is likely the conformational disease where more intensive research has been 
devoted to understand the mechanisms underlying amyloid aggregation, as well as to pinpoint its role in 
AD neuropathogenesis and as a target for anti-Alzheimer drug discovery. The specific amyloidogenic 
protein involved in AD is the -amyloid peptide (A). A is a peptide from 38 to 43 amino acids that 
arises from the proteolytic cleavage of the amyloid precursor protein (APP). Its most common form is 40 
residues in length (A40) whereas the most prone to aggregate and neurotoxic form is that of 42 residues 
(A42). According to the most widely accepted theory about the etiology of AD, the “amyloid cascade 
hypothesis”, an increased formation of A and its subsequent aggregation and deposition in neural tissue 
are the culprits of the neurodegeneration in AD patients [9-12]. A formation and aggregation are thought 
to trigger a cascade of deleterious events that eventually result in neuronal dysfunction and death and 
dementia. Thus, the discovery of inhibitors of A aggregation is an area of very active research [2,6,13-
16], together with that of other A-directed drug candidates aimed at reducing the levels of A in brain 
by inhibiting its formation (inhibitors of - and -secretases) or by increasing its clearance (active or 
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passive immunotherapy), in the search for effective medications that can delay the onset of AD and slow 
or halt its progression [16,17]. 
Usually, the screening of inhibitors of A aggregation is carried out in vitro using expensive synthetic 
peptides and thioflavin-T (Th-T)-based fluorometric assays involving a variety of experimental 
conditions [18-22]. Even in vitro, A aggregation itself is a difficult process to study, inasmuch as it is 
highly sensitive to a number of factors including purity and experimental conditions such as solvents or 
buffers used or mixing conditions [16]. Moreover, in general, in vitro evaluation of compounds against 
isolated protein targets is increasingly perceived as being too far from the (patho)physiological conditions 
where drugs have to act, with implications regarding the relevance or reliability of the obtained in vitro 
activity results when translated to the in vivo context. Indeed, in living organisms proteins are prone to 
associate and interact with other cellular components, giving rise to complex interaction networks [23,24] 
that are absent in in vitro tests [25]. Thus, in vivo A aggregation is dependent on a number of factors that 
define its complex cellular environment [1,26,27], which cannot be captured in in vitro assays. Indeed, it 
has been suggested that A aggregation can proceed through different pathways in vitro and in vivo 
thereby leading to different A aggregates [12].  
The study of A aggregation and the screening of A anti-aggregating hit or lead compounds would 
greatly benefit from novel phenotypic assays that can recapitulate key aspects of the (patho)physiological 
process of A aggregation that are absent in in vitro assays [25], and that can be more cost-effective and 
simpler than classical in vivo assays in animal models.  
In this light, bacteria have emerged as suitable models to monitor protein aggregation [27,28]. Protein 
aggregation also occurs during the production of heterologous proteins in prokaryotic systems, giving rise 
to insoluble protein aggregates, the so-called inclusion bodies (IBs), which limits the application of 
bacteria for recombinant protein production in the biotechnology industry [29]. Contrary to the initial 
assumption that IBs consisted of disorderly deposited inactive proteins, the existence of highly ordered 
amyloid-like structures inside IBs has been recently demonstrated [30-33]. This has dramatically shifted 
the consideration of IBs from being regarded as useless “molecular dust-balls” to being considered as an 
excellent and simple but biologically relevant model to study the mechanisms of amyloid folding and 
deposition related to conformational diseases. Indeed, Wang et al. have recently reported that amyloid 
structure could be an inherent property of all heterologous proteins overexpressed in IBs [31]. In contrast 
to A, which is an intrinsically unstructured protein, the polypeptides used in the study of Wang et al. 
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[31] are globular and not associated with any disease, indicating that the formation of amyloid-like 
structures inside IBs might be a general phenomenon. Therefore, it seems that the establishment of an 
inter-backbone, hydrogen-bonded network that stabilizes related fibrillar structures enriched in the β-
sheet conformation is a common force driving protein aggregation in the cell. 
Different methodologies can be used to monitor protein aggregation in bacteria, which involve the 
fluorescence detection of either genetically encoded fusion tags such as the green fluorescent protein 
(GFP) or conformational-sensitive fluorescent dyes, prominently thioflavin-S (Th-S) [27]. Regarding the 
first methodology, we have very recently developed a new method for the detection of inhibitors of 
metal-promoted A42 aggregation using purified bacterial IBs formed by an A42-GFP fusion protein in 
Escherichia coli [34]. In this method, IBs fluorescence correlated with the aggregation level of A42, as a 
result of the kinetic competition between the folding of the GFP domain, which leads to increased 
fluorescence, and the aggregation of A42 moiety, which causes the entire fusion protein to misfold 
thereby precluding the folding of the GFP domain and leading to decreased fluorescence [34]. In the 
presence of A42 aggregation inhibitors, GFP can fold into its native structure, giving rise to the 
fluorescent signal. The main drawback of this method is that any factor that can affect GFP folding or 
aggregation rates would lead to a biased readout, irrespective of the aggregation propensity of the protein. 
To overcome potential effects of the inhibitor compounds on GFP folding that might mask their anti-
amyloid capacity, the presence of amyloid aggregates inside bacteria might be directly monitored by 
using conformational-sensitive fluorescent dyes [35]. The most commonly used amyloid specific dyes are 
Th-S, Th-T, and Congo Red (CR), and among them, Th-S is the most convenient for in vivo detection of 
amyloid deposits, including bacterial IBs, by virtue of its ability to cross membranes and to penetrate 
inside the cells without interfering with the amyloid processes. Th-S is superior to CR, which possesses 
intrinsic amyloid inhibition capacity [36], and to the less lipophilic P-glycoprotein substrate Th-T, which 
cannot conveniently internalize in bacterial cells [37]. Th-S binds to amyloid fibrils, displaying an 
intensity increment and a maximum shift of its fluorescence spectrum upon binding [38]. Accordingly, 
Th-S stained amyloid-like aggregates display specific fluorescence when excited by UV or blue light 
[35,39,40].  
Herein, we describe a new effective method for the screening of putative amyloid aggregation inhibitors, 
based on the direct Th-S staining of bacterial IBs in intact E. coli cells. This method is simpler and 
cheaper than classical in vitro and in vivo assays and physiologically more relevant than the commonly 
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used in vitro tests, albeit, of course, less relevant than in vivo studies in animals or in humans. Moreover, 
this method avoids the use of reporter proteins, thus preventing potential interferences of factors affecting 
the folding of the reporter protein. In order to assess the applicability of the method we have determined 
the in vivo A42 anti-aggregating activity in intact E. coli cells of a number of compounds with well-
characterized in vitro inhibitory activity: the commercially available bioactive compounds o-vanillin and 
propidium iodide, the anti-AD drugs tacrine and donepezil, and the anti-AD investigational compounds 
(±)-huprine Y and heterodimers 1-5 (Fig. 1). Moreover, to demonstrate that this method can be applied to 
other amyloidogenic proteins, we have set up an analogous methodology for the screening of inhibitors of 
the aggregation of tau protein and we have applied it to the evaluation of some selected compounds.  
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Fig. (1). Chemical structures of the tested compounds. 
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2. MATERIALS AND METHODS 
2.1. General 
Th-S (T1892) and other chemical reagents were purchased from Sigma (St. Louis, MO). (±)-Huprine Y 
and compounds 1-5 were prepared as previously described [41-44]. Microbiological reagents were 
purchased from Conda Lab. (Spain) and isopropyl -D-thiogalactopyranoside (IPTG) from Apollo 
Scientifics (UK). Solutions were prepared in double-distilled water purified through a Milli-Q system 
(Millipore, USA). Th-S and inhibitors were solubilized in DMSO at 2.5 mM and 10 mM, respectively. 
2.2. Bacterial Growth and Protein Expression  
2.2.1. Bacterial Growth  
E. coli competent cells BL21(DE3) were transformed with a pET28a vector (Novagen, Madison, WI) 
carrying the DNA sequence of Aβ42. As a non-amyloid protein control, competent cells 
BL21(DE3)pLysS were transformed with a pET21 vector (Novagen, Madison, WI) carrying the DNA 
sequence of HET-s(1-227) expressed as a C-terminal histidine-tagged construct. In order to obtain a 
homogenous bacterial culture stock to favour the reproducibility of the assays, 25 mL of DYT medium 
(tryptone, yeast extract, NaCl) with adequate antibiotic (kanamycin or ampicillin and chloramphenicol for 
BL21(DE3) and BL21(DE3)pLysS, respectively) were inoculated with a single colony from solid media 
of E. coli BL21 bearing each plasmid to be expressed at 37 °C. Bacterial cultures were grown up 
overnight at 37 ºC. Then, 12.5 mL of sterile glycerol (60%) were added obtaining a final glycerol 
concentration of 20%. OD600 were checked and the cultures were diluted in the same media (20% glycerol 
in DYT with the required antibiotic) at OD600nm of 1. Finally, 100 L of bacterial culture were placed in 
eppendorf tubes of 1.5 mL and the tubes were frozen at -80 ºC until next use. 
For tau protein production, E. coli BL21 (DE3) competent cells were transformed with pTARA 
containing the RNA-polymerase gen of T7 phage (T7RP) under the control of the promoter PBAD. E. coli 
BL21 (DE3) with pTARA competent cells were transformed with pRKT42 vector encoding four 
repetitions of tau protein in two inserts. For overnight culture preparation, 10 mL of M9 medium 
containing 0.5% of glucose, 50 μg·mL-1 of ampicillin and 12.5 μg·mL-1 of chloramphenicol were 
inoculated with a colony of BL21 (DE3) bearing the plasmids to be expressed at 37 °C. After overnight 
grown, the OD600 is usually 2 – 2.5. 
2.2.2. Protein Expression 
For expression of A42 peptide and non-amyloid protein and controls, we added 870 L of DYT medium 
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containing the required antibiotics to the previously frozen cultures (100 L) and finally 10 L of IPTG 
(at 0.1 mM), 10 L of Th-S (at 2.5 mM) and 10 L of DMSO (in order to use the same amount of DMSO 
in the absence of inhibitor). It is known that DMSO concentrations of 2% do not affect either the amyloid 
formation or the bacterial survival [45-46]. The samples were grown for 24 h at 37 °C and 1,400 rpm 
using a Thermomixer (Eppendorf, Hamburg, Germany). For non-induced controls, 10 L of sterile 
double-distilled water were used in substitution of IPTG. 
For expression of tau protein, 20 L of overnight culture were transferred into eppendorf tubes of 1.5 mL 
containing 980 L of M9 medium with 0.25% of arabinose, 50 μg·mL-1 of ampicillin, 12.5 μg·mL-1 of 
chloramphenicol, and 10 M of each testable drug in DMSO. The samples were grown for 24 h at 37 °C 
and 1,400 rpm using a Thermomixer (Eppendorf, Hamburg, Germany). In the negative control (without 
drug) the same amount of DMSO was added in the sample. 
2.3. Thioflavin-S (Th-S) Steady-State Fluorescence 
Fluorescent spectral scans of Th-S were analyzed using an Aminco Bowman Series 2 luminescence 
spectrophotometer (Aminco-Bowman AB2, SLM Aminco, Rochester, NY). For emission and excitation 
scans, ranges from 390 to 600 nm and from 300 to 400 nm using excitation and emission wavelengths of 
375 and 455 nm, respectively, were performed. Excitation and emission slit widths of 5 nm were used. 
Spectra were acquired at 1 nm intervals and 500 nm·min-1 rates. 
For the fluorescence assay of bacterial cultures, the fluorescence emission of 25 M of Th-S at 455 nm, 
when exciting at 375 nm, was recorded. Culture media as DYT medium can dramatically interfere with 
the Th-S fluorescence signal and the differences in bacterial cells concentration might also slightly affect 
the Th-S relative fluorescence due to both bacterial membranes staining and scattering. Thus, both the 
presence of controls and an accurate determination of bacterial cell concentration are necessary to attain 
an unbiased quantification of the effect of each inhibitor. On the one hand, the Th-S fluorescence was 
normalized as a function of the bacterial concentration, determined by OD600 using a Shimadzu UV-2401 
PC UV-Vis spectrophotometer (Shimadzu, Japan). On the other hand, the normalized Th-S relative 
fluorescence was determined both in the presence and in the absence of protein expression (with or 
without IPTG). In the present work, the ratios between the normalized Th-S fluorescence of BL21(DE3) 
cells expressing and non-expressing the A42 peptide or tau protein were considered to correspond to 
100% of relative fluorescence or 0% of inhibitory activity and used as positive control. Similarly, the 
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relationship between induced and non-induced BL21(DE3)pLysS cells containing pET21 and pET28 
empty vectors was taken as negative control, corresponding to 0% of relative fluorescence or 100% of 
inhibitory effect. Besides, a non-amyloid protein as HET-s(1-227) globular domain [48] that does not 
form IBs (data not shown), and BL21(DE3)pLysS cells without any vector were also used as additional 
negative controls. By proceeding in this way a fast and accurate determination of the inhibitory activity of 
each compound could be carried out. Since both bacterial growth and protein expression can undergo 
important fluctuations among samples we carried out ten independent experiments for each assay 
condition and used the averaged value to compare inhibitors potency. 
2.4. SDS-PAGE and Western Blotting 
In order to monitor the A42 peptide concentration in cell cultures in the presence and absence of 
inhibitors, bacterial cells were pelleted by centrifugation at 14,000 rpm (5 min, 4 ºC) and frozen at -80 ºC 
for 2 h. Then, cell pellets from 1 mL culture were re-suspended in phosphate buffer saline (PBS) at the 
indicated concentrations and were analyzed by SDS-PAGE followed by Western blotting onto 
nitrocellulose membranes. To visualize A42, membranes were blocked in milk, stained with anti-A 
mAb 6E10 (1:2000, Covance), anti-mouse Ab-HRP and developed by using the Western Lightning ECL 
kit (Perkin–Elmer, Germany). 
2.5. Optical Fluorescence Microscopy 
For optical fluorescence microscopy analysis, cultures were collected after overnight induction and 
washed in PBS buffer; non-induced bacterial cultures were used as a control. Afterward, bacterial cells 
were incubated for 1 h in the presence of 125 M Th-S. In order to avoid the residual Th-S fluorescence 
of the free dye the samples were centrifuged at 3,500g for 5 min and the obtained precipitate fraction 
was re-suspended in PBS. 10 μL of sample was collected and deposited on top of glass slides. Images 
were obtained under UV light or phase-contrast using a Leica fluorescence DMBR microscope (Leica 
Microsystems, Mannheim, Germany). 
 
3. RESULTS AND DISCUSSION 
Th-S staining coupled to flow cytometry has been recently reported to be an excellent screening tool to 
monitor protein aggregation in intact E. coli  cells, offering advantages for the analysis of biological 
samples over conventional single-cell measurements or approaches that rely on averaged population 
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properties [35]. Unfortunately, flow cytometry is not yet a readily available tool in the majority of 
research labs. Herein we show that Th-S relative fluorescence upon in vivo binding to amyloid-like 
proteins can be used as an alternative simple method to assess the effect of putative anti-aggregation drug 
candidates. 
The self-assembly in -sheet conformation of A appears to play a major causative role in AD 
neuropathogenesis [9-12]. As discussed previously, bacterial cells can be useful systems for studying in 
vivo protein aggregation, providing a biologically relevant environment for the screening of anti-
aggregation drugs [30]. Because overexpression of A40 and A42 in bacteria entails the formation of 
IBs that display amyloid-like properties [32], here we have chosen A42, the most aggregation-prone and 
neurotoxic A peptide, to test the applicability of our method.  
In order to confirm the Th-S binding to intracellular aggregates we visualized A42 IBs using 
microscopy under UV-light. As shown in Fig. 2, A42 IBs are selectively stained inside living bacterial 
cells yielding a bright green-apple fluorescence, displaying a maximal excitation and emission 
fluorescence at 375 and 455 nm, respectively. For the positive control a ratio of 1.8 between the 
maximum of fluorescence of BL21(DE3) expressing and non-expressing the A42 peptide was obtained. 
For the negative control (BL21(DE3)pLysS containing the pET21 and pET28 empty vectors and/or the 
same cells without any vector) a ratio of 1 between induced and non-induced cultures was found. As 
expected, the non-amyloid and soluble HET-s(1-227) domain displays a ratio of 1.1, very close to those 
obtained for negative controls. 
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 Fig. (2). Th-S staining of bacterial cells overexpressing A42 peptide. (A) Optical fluorescence 
microscopy images of bacterial cells overexpressing Aβ42 peptide stained with Th-S. The microscopy 
image under UV light shows the presence of amyloid-like IBs localized at the cellular poles. Scale bars 
0.5 m. (B) Emission and excitation spectra of Th-S in the presence of bacterial cells overexpressing 
Aβ42 peptide. Note that excitation and emission wavelengths of 375 and 455 nm have been used, 
respectively. 
 
Proceeding in the same manner with BL21(DE3) cells expressing A42 in the presence of putative anti-
aggregating compounds, a fast and accurate evaluation of the effect of each inhibitor can be performed. In 
order to discard possible adverse effects of the inhibitors on bacterial cell survival and/or A42 
expression, we monitored the OD600 of each cell culture and the A42 expression level by Vis 
spectroscopy and western blotting, respectively. Non-induced cultures showed OD600 1.30.1 at the final 
growth time, whereas the induced ones displayed OD600 0.90.1 at the same incubation time. Very 
similar results were observed in the presence of all anti-aggregation compounds (data not shown). 
Moreover, western blotting assays showed that the protein expression levels were not altered by the 
presence of the tested compounds. 
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When bacterial cells overexpressing A42 were incubated in the presence of 10 M of inhibitors, for 
which in vitro A42 anti-aggregating activities had been previously reported, we observed in all cases a 
decrease in the final Th-S relative fluorescence per cell. This is a consequence of the diminution of 
amyloid-like structures in bacterial cells, and therefore, of the in vivo inhibitory activity of the tested 
compounds in the intact E. coli cells. In Fig. 3 it can be observed that in the presence of active inhibitors, 
as propidium, the Th-S staining is significantly reduced whereas poorly active compounds, such as (±)-
huprine Y, almost do not affect Th-S staining relative to controls (Fig. 3, upper panel). 
 
 
 
Fig. (3). Th-S staining of bacterial cells overexpressing A42 peptide in the absence and in the presence 
of active (propidium) and inactive ((±)-huprine Y)) anti-aggregating compounds. (A) Optical 
fluorescence microscopy images of bacterial cells overexpressing Aβ42 peptide stained with Th-S. (B) 
Th-S relative fluorescence in the presence of bacterial cells overexpressing Aβ42 peptide. Note that 
excitation and emission wavelengths of 375 and 455 nm have been used, respectively. 
 
Very interestingly, all tested compounds exhibited anti-aggregating activities in intact E. coli cells similar 
to those observed in vitro (Fig. 4 and Table 1 of Supplementary Material). Also, the order of A42 anti-
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aggregating potencies of the tested compounds found in the in vivo assays almost perfectly matches that 
reported in vitro. Thus, (±)-huprine Y, tacrine and donepezil, which had been reported to be essentially 
inactive in vitro as A42 anti-aggregating compounds, display very low A42 anti-aggregating activity in 
E. coli, with percentages of inhibition of 9.2%, 4.3%, and 2.5%, respectively, whereas heterodimeric 
compounds 1-3 and 5 as well as other known A42 anti-aggregating compounds as propidium iodide and 
o-vanillin display significant inhibitory activities, with percentages of inhibition ranging from 23.5% to 
48.5%. Heterodimer 4 exhibited a very low activity as it had been previously found in vitro (28.6% 
inhibition at 50 μM) [42]. 
 
Fig. (4). Inhibitory activities of anti-aggregating compounds monitored by Th-S staining of bacterial cells 
overexpressing A42 peptide. The graph shows the anti-aggregating effect of 10 M of inhibitor added to 
bacterial culture overexpressing A42 peptide after overnight incubation. The grey section in each bar 
denotes the reported inhibitory activity of each compound by in vitro determinations using a drug:A42 
ratio of 1:5 [42-44,49]. () Note that the in vitro inhibitory activity of these drugs was determined using a 
concentration of inhibitor of 50 μM and a drug/A42 ratio of 1:1 [42]. () In vitro data obtained using a 
concentration of inhibitor of 300 μM and a drug:A42 ratio of 1:0.15 [50]. In the upper part of the figure, 
western blotting of bacteria cells in the absence or in the presence of drugs are shown. Note that similar 
concentration of A42 is detected in the absence and in the presence of inhibitors. 
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 Worthy of note, all in vivo inhibitory activities are lower than those reported in vitro, with the sole 
exception of compound 3, which displayed the same potency in vivo and in vitro. The drug:A42 
stoichiometry might explain this fact; in vitro assays are carried out at a ratio 1:1 or 1:5, whereas in in 
vivo studies the stoichiometry might be very different. On the one hand, we performed our assays at 10 
M of drug whereas the concentration of A42 might be clearly higher. On the other hand, the intrinsic 
capacity of each drug to cross the bacterial membrane might restrict the inhibitor concentration in the cell. 
Even if the capability of a drug to cross biological membranes is a desirable property, some initial hits 
that are unable to cross E. coli membranes but active as A42 aggregation inhibitors would remain 
undetected, and therefore lost, in the in vivo screen, which represents a flaw of this methodology. 
Finally, we decided to investigate if our protocol allowed the quantification of the anti-aggregating 
activity in a dose-dependent manner. In Fig. 5 we show that for compounds 4 and 5 and propidium iodide 
(selected because in vitro inhibitory activities at different drug:A42 stoichiometries are available 
[42,49]) an increased A42 anti-aggregating activity was observed for the higher drug concentrations (see 
also Table 2 of Supplementary Material). 
 
Fig. (5). Dosage of anti-aggregating activity monitored by Th-S staining of bacterial cells overexpressing 
A42 peptide. Note that the grey section in each bar denotes the reported value of each inhibitor obtained 
by in vitro determinations [42,49]. 
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 Given the structural and tinctorial similarities between amyloid aggregates of different proteins, we 
thought that our methodology might be applied to other amyloidogenic proteins that form IBs when 
overexpressed in E. coli cells. Apart from A42, another amyloidogenic protein, namely the tau protein, 
seems to play a pivotal role in the onset and progression of the neurodegenerative cascade of AD. This 
prompted us to assess the applicability of our methodology to the screening of the tau anti-aggregating 
effect of potential inhibitors in intact E. coli cells overexpressing tau protein. For this purpose, we 
selected tacrine and (±)-huprine Y, which had been found to be essentially inactive as A42 aggregation 
inhibitors both in vitro and in E. coli cells, and compound (±)-1, which had been found to be active. As 
expected, when bacterial cells overexpressing tau protein were incubated in the presence of 10 M of 
these selected compounds we found that tacrine and (±)-huprine Y were again inactive as anti-
aggregating agents whereas heterodimer (±)-1 inhibited tau protein aggregation in a very remarkable 67.6 
± 2.1% (Fig. 6). These results support the applicability of this method for the screening of inhibitors of 
different disease-specific amyloidogenic proteins as well as the increasingly accepted notion that 
amyloidoses might be confronted with common therapeutic interventions [51]. 
 
Fig. (6). Aggregation inhibitory activities of selected compounds monitored by Th-S staining of bacterial 
cells overexpressing tau protein. The graph shows the anti-aggregating effect of 10 M of inhibitor added 
to bacterial culture overexpressing tau protein after overnight incubation. 
 
The possibility of applying this method in automated technologies available for cell-based screening, like 
simple UV/Vis plate reader assays, might allow the in vivo analysis of large compound libraries at 
different stoichiometric ratios using this fast, simple, quantitative and cost-effective method. 
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4. CONCLUSION 
Prokaryotic cells can provide a simple yet physiologically relevant model to study the mechanisms and 
extent of amyloid aggregation of peptides and proteins related to conformational diseases. Interestingly, 
bacterial systems can be easily implemented to study the effect of genetic mutations [52-55] and/or the 
effects of drugs [56] on the aggregation of amyloid-prone proteins. We present here a protocol in which 
the direct determination of the Th-S relative fluorescence of bacterial cells allows to monitor changes in 
the intracellular aggregation of amyloidogenic proteins, without the requirement for expensive 
equipment. The method can be potentially applied to track the effects of target compounds and sequential 
changes on the deposition of different amyloidogenic proteins. The ability of the method to recapitulate 
previous in vitro results regarding A42 anti-aggregating activity suggests that it can become a standard 
able to replace non-physiological in vitro assays in the next future. 
 
LIST OF ABBREVIATIONS 
A = -Amyloid peptide 
AD = Alzheimer’s disease 
APP  = Amyloid precursor protein 
CR = Congo Red 
GFP  = Green fluorescent protein 
IBs = Inclusion bodies 
IPTG = Isopropyl -D-thiogalactopyranoside 
PBS  = Phosphate buffer saline 
Th-S  = Thioflavin-S  
Th-T  = Thioflavin-T 
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